News

September 21, 2021

EMulate Therapeutics Announces Positive Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Demonstrates Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs

Read More

August 9, 2021

Hapbee Expands Leadership Team to Support Aggressive Growth Strategy

Read More

July 28, 2021

Hapbee Users Log Over 1 Million Hours of Use for Sleep, Focus and Alertness Signals

Read More

March 17, 2021

EMulate Therapeutics to Participate in the Venture Summit \ Virtual Connect West on March 17 at 12pm PST

Read More

March 17, 2021

EMulate Therapeutics: Ushering in a New Era in Non-Invasive Cancer Therapy

Read More

December 30, 2020

A Medical Technology That Has The Highest Potential Over Any We Follow

Read More

December 18, 2020

Hapbee Commences Trading on the Frankfurt Exchange Under the Symbol “HA1”

Read More

December 17, 2020

Hapbee Announces Additions to Advisory Board

Read More

December 2, 2020

Hapbee Announces Launch of A Subscription-Based Wellbeing Wearable, Providing Members the Ability to Choose ‘How They Feel’

Read More

December 1, 2020

Hapbee Advances New Signals into Closed Beta Phase

Read More

Older »